Thymosin Beta-4 Dosage Guide: Research Protocols, Timing & Reconstitution

Standard Dosage Range

Research dosing range: 2–10 mg per dose (injection); variable for topical use

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Wound Healing / Tissue Repair

2–6 mg1–2× daily

Duration

4–8 weeks

Inject subcutaneously near the injury site. Many prefer bilateral injection closest to the area being targeted. Most preclinical studies used a 4-week protocol.

Cardiac Repair (post-MI)

5–10 mg1× daily

Duration

4–12 weeks

Subcutaneous injection. Based on early clinical trial protocols, aiming to promote cardiac progenitor cell activation. Limited human data available.

Dry Eye Disease

Variable2–4× daily

Duration

Ongoing

Topical ophthalmic solution. Clinical trials use varying concentrations. Consult with an ophthalmologist.

Neuroprotection / TBI

2-5 mg1× daily

Duration

4–12 weeks

Evidence is preliminary (animal models only). Subcutaneous administration is the practical analog for research purposes.

Systemic Anti-Inflammatory

2-4 mg1× daily

Duration

4–8 weeks

Subcutaneous. Not yet validated in human trials.

Timing & Frequency

For musculoskeletal applications, injections are typically administered in the morning or post-workout, near the injury site. TB4 has an estimated half-life of ~1 hour, supporting twice-daily dosing for sustained coverage in preclinical models.

Cycle Guidance

Most preclinical studies ran 4–8 week protocols. Common research practice uses a 6–12 week cycle followed by a 4-week break. Cycling rationale is primarily precautionary given limited long-term human safety data.

Reconstitution Reference

Quick reference for reconstituting Thymosin Beta-4. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial Size	Typically 10 mg per vial
BAC Water Volume	5 mL bacteriostatic water for 2 mg/mL concentration
Concentration & Draw	At 2 mg/mL: 2 mg = 1 mL (100 units on a 100-unit insulin syringe)
Storage	Refrigerate at 2–8°C after reconstitution. Keep lyophilized powder at room temperature or refrigerated.
Stability	Reconstituted solution stable up to 30 days refrigerated. Lyophilized powder stable 12-24 months per manufacturer specifications.

Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the standard Thymosin Beta-4 dosage for tendon injury?

Preclinical research typically uses 2-6 mg per dose, administered 1-2 times daily via subcutaneous injection near the injured tendon. Most research community protocols use a similar range for research purposes, but no definitive human dose-ranging studies exist.

How should I store Thymosin Beta-4 after reconstitution?

Reconstituted Thymosin Beta-4 solution should be refrigerated at 2–8°C and is generally stable for up to 30 days. The lyophilized powder should be stored at room temperature or refrigerated prior to reconstitution.

Can Thymosin Beta-4 be used orally?

While subcutaneous injection is the most common route of administration, some anecdotal reports suggest potential oral bioavailability. However, there is limited scientific evidence to support oral administration of Thymosin Beta-4, and its effectiveness via this route is uncertain.

Are there any known drug interactions with Thymosin Beta-4?

No significant drug interactions have been formally reported with Thymosin Beta-4. However, caution is advised when combining it with other anti-inflammatory agents or medications affecting wound healing, as synergistic or antagonistic effects are possible.